8-K: CytoSorbents Announces Strong Preliminary Q4 and Full-Year 2024 Revenue Growth

CytoSorbents reported preliminary unaudited fourth quarter and full-year 2024 results, highlighting significant revenue growth and improved gross margins.

Summary

• CytoSorbents Corporation announced preliminary unaudited financial results for the fourth quarter and full year of 2024.
• Fourth quarter product revenue is estimated to be between $9.0 million and $9.2 million, a 22% to 25% increase compared to $7.35 million in the same quarter of 2023.
• Full-year product revenue is estimated to be between $35.4 million and $35.6 million, representing approximately 14% growth compared to $31.1 million in 2023.
• The fourth quarter gross margin is estimated to be approximately 70%, an improvement from 61% in the previous quarter but slightly lower than the 72% in the fourth quarter of 2023.
• The company has commenced a rights offering on December 23, 2024, with a subscription period ending on January 10, 2025.
• Regulatory reviews are underway for DrugSorb-ATR in the U.S. and Canada, with decisions expected in 2025.
• The company expects to report full, audited results for the fourth quarter and year ended December 31, 2024, on March 6, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improved gross margins. The company is also progressing with regulatory approvals and investor engagement, indicating a positive trajectory.

Positives

• The company experienced strong year-over-year revenue growth in both the fourth quarter and full year of 2024.
• The gross margin improved significantly in the fourth quarter compared to the third quarter of 2024.
• The company is progressing with regulatory submissions for DrugSorb-ATR in the U.S. and Canada.
• The company is actively engaging with investors through in-person meetings.

Negatives

• The fourth quarter gross margin, while improved sequentially, is slightly lower than the same quarter in the previous year.
• The results disclosed are preliminary and unaudited.

Risks

• The company's future performance is subject to regulatory approvals for DrugSorb-ATR.
• The company's actual results may differ from the preliminary estimates.
• The company's business is subject to risks detailed in their SEC filings.

Future Outlook

The company anticipates regulatory decisions for DrugSorb-ATR in the U.S. and Canada in 2025 and expects to drive improved efficiencies in its core business as it prepares to enter the North American market.

Management Comments

• Dr. Phillip Chan, Chief Executive Officer, stated that the strong year-over-year growth represents solid execution in their core international business.
• Dr. Phillip Chan also noted that the results position the company well to drive improved efficiencies as they prepare to enter the North American market with DrugSorb-ATR.

Industry Context

CytoSorbents operates in the blood purification sector, focusing on critical care and cardiac surgery. The company's growth reflects the increasing demand for advanced medical devices in these areas. The development of DrugSorb-ATR is a key focus, targeting a specific need in reducing bleeding risks associated with certain medications.

Comparison to Industry Standards

• CytoSorbents' 22-25% revenue growth in Q4 2024 is strong compared to the broader medical device industry, which often sees single-digit growth rates.
• Companies like Baxter and Fresenius Medical Care, which are also involved in blood purification, have reported varying growth rates, but CytoSorbents' focus on a niche market with its proprietary technology may give it a competitive edge.
• The gross margin of 70% is competitive within the medical device industry, although some companies with higher-margin products may achieve higher rates.
• The regulatory pathway for DrugSorb-ATR is similar to other medical devices, but the breakthrough designation may expedite the process compared to standard approvals.

Stakeholder Impact

• Shareholders may view the strong revenue growth and improved gross margins positively.
• Employees may be encouraged by the company's positive performance and future prospects.
• Customers may benefit from the company's continued innovation and product development.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial health as improving.

Next Steps

• The company will continue the regulatory review process for DrugSorb-ATR in the U.S. and Canada.
• The company will report full, audited results for the fourth quarter and year ended December 31, 2024, on March 6, 2025.
• Management will host in-person investor meetings in San Francisco during the J.P. Morgan Healthcare Conference week.
• The company will continue to execute its core international business strategy.

Key Dates

Keywords

CytoSorbents, Product Revenue, Gross Margin, DrugSorb-ATR, Regulatory Approval, Blood Purification, Medical Device, Rights Offering, Healthcare, Financial Results